Why is Bristol-Myers Squibb buying back its own debt?

The filing does not state the rationale in detail, but the structure (paying off existing notes with newly issued debt and cash on hand) is a standard liability management transaction. It typically aims to reduce outstanding debt, refinance higher-coupon obligations, or adjust the maturity profile, and the company may be seeking to lower its interest costs over time.

What will holders of the notes receive?

Holders who validly tender by 5:00 p.m. ET on November 17, 2025 receive the Total Consideration, which equals a fixed spread plus the Treasury yield set at 10:00 a.m. ET on November 18, 2025, and includes a $50 per $1,000 early tender premium. Holders who tender later, but before the December 3, 2025 expiration, receive the Tender Consideration, which is the Total Consideration minus the premium. All accepted holders also receive accrued and unpaid interest up to the settlement date.

What happens if more notes are tendered than the pool limits allow?

If tenders exceed the $4.0 billion Pool 1 or $3.0 billion Pool 2 maximum, BMY accepts notes in order of acceptance priority level, starting with level 1. The series at the lowest accepted priority level is prorated, and notes with lower-priority levels are not accepted. Notes tendered after the early deadline are accepted only if capacity remains after early tenders are processed.

Could these offers be cancelled?

Yes. The offers are conditioned on the completion of the new notes offering with sufficient net proceeds, together with about $3.0 billion of cash, to pay for all accepted notes. BMY can waive that financing condition or terminate, extend, or amend any offer in its sole discretion, subject to applicable law. If an offer is terminated, tendered notes are returned to holders.

Does this filing reveal anything about BMY's financial performance?

No. This 8-K is a notice of the offers and does not include financial results, guidance, or updated figures on earnings or cash flow. The filing does not disclose the size or pricing of the new notes or the amount of debt that will ultimately be retired, so the financial impact on interest expense and leverage cannot be assessed from this document alone.

BRISTOL MYERS SQUIBB CO 8-K SEC Disclosure

01—Abstract

Summary

Summary of the 8-K filed November 3, 2025. Cited figures are marked; the original filing is the authoritative source.

On November 3, 2025, Bristol-Myers Squibb (BMY) announced cash tender offers to repurchase up to $7 billion^a of its outstanding notes, split into two pools: Pool 1 (up to $4.0 billion across six series maturing 2026 through 2029) and Pool 2 (up to $3.0 billion across nine longer-dated series, including 2031 through 2097 maturities).

The offers are funded by a concurrent new notes offering by its wholly-owned Irish finance subsidiary, BMS Ireland Capital Funding DAC, combined with roughly $3.0 billion^b of cash on hand. The offers are subject to a financing condition tied to that new issuance, and the company is not obligated to purchase any minimum amount of notes. The transaction is essentially a liability management exercise: BMY is retiring existing higher-coupon debt (many coupons of 5.1% to 6.9%) and refinancing it with new debt, while also reducing principal outstanding and potentially smoothing its maturity profile.

Holders who tender by the early deadline of November 17, 2025 receive a $50^c per $1,000 early tender premium plus a fixed spread over a Treasury reference yield, priced as of November 18, 2025. Later tenders receive a lower price that excludes the premium. Acceptance is governed by priority levels, with proration applied to the lowest-priority series if the pool caps are exceeded.

For investors, the filing signals active balance sheet management rather than a change in operating performance. The filing does not disclose the size or pricing of the new notes, the amount of debt actually tendered, or the resulting interest expense savings, so those effects remain to be quantified in subsequent press releases. The company also reserves the right to redeem the 2026, 2027, and 2028 notes that remain outstanding after the offers, which could be a further step in reducing its debt stack.

02—Key points

Key Highlights

BMY launched cash tender offers to buy back up to $7 billion of its outstanding notes, split into Pool 1 (up to $4.0 billion) and Pool 2 (up to $3.0 billion).
Pool 1 covers six series maturing 2026 to 2029 with fixed spreads of 10 to 20 basis points over Treasury benchmarks; Pool 2 covers nine longer-dated series maturing 2031 to 2097 with spreads of 25 to 140 basis points.
Tendering holders by the November 17, 2025 early deadline receive a $50 per $1,000 early tender premium on top of the Total Consideration; later tenders receive a lower Tender Consideration without the premium.
The offers are funded by a new notes offering from BMS Ireland Capital Funding DAC plus approximately $3.0 billion of cash on hand, and are conditioned on that financing closing.
The offers have no minimum tender threshold and are not conditioned on one another; BMY may amend, extend, or terminate them, or waive the financing condition, in its sole discretion.
Early settlement is currently expected on the third business day after the early deadline, with final settlement expected two business days after the December 3, 2025 expiration.
BMY may redeem the 2026, 2027, and 2028 notes that remain outstanding after the offers, at redemption prices that may differ materially from the tender consideration.

03—Questions

Frequently Asked Questions

Why is Bristol-Myers Squibb buying back its own debt?
The filing does not state the rationale in detail, but the structure (paying off existing notes with newly issued debt and cash on hand) is a standard liability management transaction. It typically aims to reduce outstanding debt, refinance higher-coupon obligations, or adjust the maturity profile, and the company may be seeking to lower its interest costs over time.
What will holders of the notes receive?
Holders who validly tender by 5:00 p.m. ET on November 17, 2025 receive the Total Consideration, which equals a fixed spread plus the Treasury yield set at 10:00 a.m. ET on November 18, 2025, and includes a $50 per $1,000 early tender premium. Holders who tender later, but before the December 3, 2025 expiration, receive the Tender Consideration, which is the Total Consideration minus the premium. All accepted holders also receive accrued and unpaid interest up to the settlement date.
What happens if more notes are tendered than the pool limits allow?
If tenders exceed the $4.0 billion Pool 1 or $3.0 billion Pool 2 maximum, BMY accepts notes in order of acceptance priority level, starting with level 1. The series at the lowest accepted priority level is prorated, and notes with lower-priority levels are not accepted. Notes tendered after the early deadline are accepted only if capacity remains after early tenders are processed.
Could these offers be cancelled?
Yes. The offers are conditioned on the completion of the new notes offering with sufficient net proceeds, together with about $3.0 billion of cash, to pay for all accepted notes. BMY can waive that financing condition or terminate, extend, or amend any offer in its sole discretion, subject to applicable law. If an offer is terminated, tendered notes are returned to holders.
Does this filing reveal anything about BMY's financial performance?
No. This 8-K is a notice of the offers and does not include financial results, guidance, or updated figures on earnings or cash flow. The filing does not disclose the size or pricing of the new notes or the amount of debt that will ultimately be retired, so the financial impact on interest expense and leverage cannot be assessed from this document alone.

04—Continue

← View all 8-K filings